Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2010

View Archived Issues

Studies refine CAD-106 treatment regimen

Phase I trial shows safety MABT-5102-A in patients with AD

New HPV DNA vaccine AcHERV-HP16/18L1 is immunogenic in vivo

Poly-ICR can block suppression of anti-HPV immune responses

Glenmark Pharmaceuticals claims new TRPV3 channel inhibitors

Array BioPharma discovers new DP2 receptor inhibitors

Schering discloses novel nicotinic acid receptor agonists

Chinese scientists identify novel protein kinase inhibitors

AD candidate RQ-9 improves memory and cognition in rodents

Canagliflozin improves glucose control in persons with type 2 diabetes

Renovo provides update on product pipeline

Vernalis and Biogen to replace vipadenant in Parkinson's disease program

Supernus begins phase IIa SPN-812 trial in adults with ADHD

Lantheus launches Definity ultrasound contrast imaging product in India

Biolipox presents novel PDE4/PDE7 inhibitors

Elusys and Lonza extend contract to produce Anthim for inhalation anthrax

Galapagos and Bristol University to develop agents for diabetes-associated chronic pain

Nitric Bio begins phase II trial of terbinafine/device combination in onychomycosis

GTC regains rights to recombinant antithrombin ATryn

Amgen's denosumab BLA receives FDA priority review status

Biomet acquires substantially all assets of Cytosol Laboratories

Cangene's option to license Maxygen's MAXY-G34 for ARS expires

FDA extends PDUFA date for Walter Chilcott's Actonel product

Novo Nordisk completes recruitment in A1chieve trial of insulin regimens

Evotec gains new alliances in acquisition of DeveloGen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...